Ontak
Drug
Eisai Inc.
Total Payments
$6.5M
Transactions
3,956
Doctors
16
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,690 | 1 | 0 |
| 2023 | $80,975 | 35 | 1 |
| 2022 | $1.1M | 422 | 2 |
| 2021 | $662,582 | 392 | 6 |
| 2020 | $1.3M | 906 | 3 |
| 2019 | $1.8M | 1,121 | 0 |
| 2018 | $1.4M | 869 | 0 |
| 2017 | $262,088 | 210 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.4M | 3,894 | 98.2% |
| Consulting Fee | $116,290 | 47 | 1.8% |
| Food and Beverage | $537.40 | 15 | 0.0% |
Payments by Type
Research
$6.4M
3,894 transactions
General
$116,827
62 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma | Eisai Inc. | $5.2M | 0 |
| A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma | Eisai Inc. | $1.2M | 0 |
| A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma | EISAI INC. | $22,290 | 1 |
Top Doctors Receiving Payments for Ontak
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Palo Alto, CA | $6.4M | 3,887 |
| , M.D | Hematology & Oncology | Boston, MA | $38,700 | 11 |
| , MD | Hematology & Oncology | Boston, MA | $24,490 | 9 |
| , M.D | Dermatology | Boston, MA | $21,200 | 7 |
| , M.D | Specialist | Marion, IN | $16,810 | 2 |
| , MD | Dermatology | Burlington, MA | $14,720 | 10 |
| Asim Farooq | Ophthalmology | Cook, IL | $13,000 | 3 |
| , MD | Diagnostic Radiology | Boston, MA | $8,120 | 7 |
| , M.D | Diagnostic Radiology | Boston, MA | $1,540 | 5 |
| , MD | Medical Oncology | New Haven, CT | $98.90 | 3 |
| , MD | Hematology & Oncology | Duarte, CA | $80.23 | 2 |
| , MD | Hematology | Tampa, FL | $80.23 | 2 |
| , M.D | Hematology | Hackensack, NJ | $80.23 | 2 |
| , M.D | Hematology & Oncology | Duarte, CA | $80.23 | 2 |
| , M.D | Dermatology | Houston, TX | $80.23 | 2 |
| , MD | Dermatology | Stanford, CA | $18.68 | 1 |
| , M.D | Dermatology | Houston, TX | $18.67 | 1 |
Ad
Manufacturing Companies
- Eisai Inc. $6.5M
- EISAI INC. $45,950
Product Information
- Type Drug
- Total Payments $6.5M
- Total Doctors 16
- Transactions 3,956
About Ontak
Ontak is a drug associated with $6.5M in payments to 16 healthcare providers, recorded across 3,956 transactions in the CMS Open Payments database. The primary manufacturer is Eisai Inc..
Payment data is available from 2017 to 2024. In 2024, $1,690 was paid across 1 transactions to 0 doctors.
The most common payment nature for Ontak is "Unspecified" ($6.4M, 98.2% of total).
Ontak is associated with 3 research studies, including "A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma" ($5.2M).